# EDGAR Filing Document

**Accession Number:** 0001812173
**File Stem:** 0001213900-25-070028
**Filing Date:** 2025-7
**Character Count:** 53039
**Document Hash:** 95252177b2e82c620c21de6ac86dda4d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-070028.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001213900-25-070028

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250730

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vicarious Surgical Inc.
- **CENTRAL INDEX KEY:** 0001812173
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39384
- **FILM NUMBER:** 251172130

**BUSINESS ADDRESS:**
- **STREET 1:** 78 FOURTH AVENUE
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** (617) 868-1700

**MAIL ADDRESS:**
- **STREET 1:** 78 FOURTH AVENUE
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** D8 Holdings Corp.
- **DATE OF NAME CHANGE:** 20200514

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 30, 2025**

**VICARIOUS SURGICAL INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39384** | **87-2678169** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **78 Fourth Avenue**<br>**Waltham, Massachusetts** | **02451** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(617) 868-1700**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on<br> which registered** |
| Class A common stock, par value $0.0001 per share | RBOT | The New York Stock Exchange |
| Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share | RBOT WS | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Appointment of Chief Executive Officer and Director*

 

On July 30, 2025, the Board of Directors (the "Board") of Vicarious Surgical Inc. (the "Company") appointed Stephen From as Chief Executive Officer of the Company, effective as of August 7, 2025 (the "Effective Date"). The Board also approved an increase to the size of the Board and the appointment of Mr. From to the Board to fill the resulting vacancy, in each case effective as of the Effective Date and subject to the commencement of Mr. From's employment on that date.

Mr. From, age 62, has served as Chief Executive Officer of Aruna Bio from April 2022 through the present, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and Chief Executive Officer, and from February 2021 through January 2022 served as Executive Chairman, of Kiora Pharmaceuticals, Inc., formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space. Prior to EyeGate, Mr. From served as the Chief Financial Officer of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.

There are no arrangements or understandings between Mr. From and any other person pursuant to which he was appointed to serve as Chief Executive Officer of the Company. There are no family relationships between Mr. From and any director or executive officer of the Company, and Mr. From does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

*Appointment of President*

 

Also on July 30, 2025, the Board appointed Adam Sachs, the Company's current Chief Executive Officer, as President of the Company, effective as of the Effective Date. Biographical and other information about Mr. Sachs is included in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025, and is hereby incorporated by reference.

There are no arrangements or understandings between Mr. Sachs and any other person pursuant to which he was appointed to serve as President of the Company. There are also no family relationships between Mr. Sachs and any director or executive officer of the Company, and Mr. Sachs does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

*Employment Agreement*

 

In connection with Mr. From's appointment as Chief Executive Officer, on July 30, 2025, the Company entered into an Executive Employment Agreement (the "Employment Agreement") with Mr. From. Pursuant to the Employment Agreement, Mr. From will serve as the Company's Chief Executive Officer and report directly to the Board or its designee. Mr. From's service pursuant to the Employment Agreement will continue until terminated in accordance with its terms.

Under the Employment Agreement, Mr. From will receive an annual base salary of $500,000, and will be eligible to receive an annual performance bonus targeted at 50% of Mr. From's then-current annual base salary. The actual amount of any bonus will be determined by reference to the attainment of applicable Company and/or individual performance objectives, as determined by the Board. Pursuant to the Employment Agreement, Mr. From is also eligible to participate in customary welfare and fringe benefit plans, provided by the Company to its employees at the same level as Mr. From.

The Employment Agreement provides that, subject to the approval of the Board and the Compensation Committee of the Board, the Company will grant to Mr. From a non-qualified stock option (the "Option") exercisable for up to 297,600 shares of the Company's Class A common stock. Twenty-five percent of the Option will vest on the one-year anniversary of its grant date and the remainder will vest in 36 consecutive, equal monthly installments, subject to Mr. From's continued service to the Company through each vesting date. The Option will be granted as a material inducement to Mr. From entering into employment with the Company pursuant to Section 303A.08 of the New York Stock Exchange Listed Company Manual. Consequently, the Option will be made outside of the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), but will be subject to terms and conditions generally consistent with those in the Plan.

In the event that Mr. From is terminated without Cause or resigns from his position for Good Reason, as such terms are defined in the Employment Agreement, he will, subject to execution of a separation agreement in a form acceptable to the Company, be entitled to receive a severance payment in the form of salary continuation payments for twelve months of his base salary.

The Company will reimburse Mr. From for all ordinary and reasonable out-of-pocket business expenses incurred by Mr. From in furtherance of the Company's business in accordance with the Company's policies with respect thereto as in effect from time to time. Mr. From will also be subject to the Company's Non-Competition and Non-Solicitation Agreement and Invention and Non-Disclosure Agreement, which impose certain post-employment restrictive covenants.

The foregoing description of the Employment Agreement is a summary and does not purport to be complete. Such description is qualified in its entirety by reference to the text of the Employment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

**Item 7.01. Regulation FD Disclosure.**

On July 31, 2025, the Company issued a press release announcing the appointment of Mr. From as Chief Executive Officer and Mr. Sachs as President. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d)** **Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Executive Employment Agreement, dated as of July 30, 2025, between Vicarious Surgical Inc. and Stephen From](ea025105101ex10-1_vicarious.htm) |
| 99.1 | [Press Release dated July 31, 2025](ea025105101ex99-1_vicarious.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **VICARIOUS SURGICAL INC.** | **VICARIOUS SURGICAL INC.** |
| By: | /s/ Adam Sachs |
| Name: | Adam Sachs |
| Title: | Chief Executive Officer |

---

Date: July 31, 2025

## Exhibit 10.1

**Exhibit 10.1**

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the "Agreement"), is made and entered into this 30th day of July, 2025 (the "Execution Date"), and is by and between Vicarious Surgical Inc. ("Company"), and Stephen From ("Executive").

WHEREAS, Company wishes to employ Executive to serve as its Chief Executive Officer;

WHEREAS, Executive represents that Executive possesses the necessary skills to perform the duties of this position and that Executive has no obligation to any other person or entity which would prevent, limit or interfere with Executive's ability to do so; and

WHEREAS, Executive and Company desire to enter into a formal Executive Employment Agreement to assure the harmonious performance of the affairs of Company.

NOW, THEREFORE, in consideration of the mutual promises, terms, provisions, and conditions contained herein, the parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Title and Duties</u>. Subject to the terms and conditions of this Agreement, Executive's position with Company shall be Chief Executive Officer reporting to Company's Board of Directors (the "Board") or the Board's designee. Executive accepts such employment upon the terms and conditions set forth herein, and agrees to perform to the best of Executive's ability the duties normally associated with such position and as reasonably determined by the Board in its sole discretion, including without limitation complying with all Company policies and procedures, the Company Code of Business Conduct and Ethics and Company values. While serving hereunder, Executive shall devote all of Executive's business time and energies to the business and affairs of Company, <u>provided</u> that nothing contained in this Section 1 shall prevent or limit: (a) Executive's right to manage Executive's personal investments on Executive's own personal time, including, without limitation the right to make passive investments in the securities of (i) any entity which Executive does not control, directly or indirectly, and which does not compete with Company, or (ii) any publicly held entity, so long as Executive's aggregate direct and indirect interest does not exceed two percent (2%) of the issued and outstanding securities of any class of securities of such publicly held entity; (b) Executive's participation in civic and charitable activities, including as a member of a board of a civic or charitable organization, so long as such activities do not interfere with Executive's performance of Executive's duties hereunder; and (c) Executive's participation as an advisor to, or director of, up to two (2) entities that are not competitors of Company, subject to Company's prior written approval, which will not be unreasonably withheld. In addition, the Company shall, as soon as reasonably possible, take the steps necessary to add the Executive to the Company's Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Term; Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Term</u>. The terms of Executive's employment set forth herein shall be effective August 7, 2025 (the "Effective Date") and thereafter shall continue until terminated hereunder by either party (such term of employment shall be referred to herein as the "Term").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Termination by Company</u>. Notwithstanding anything else contained in this Agreement, from and after the Effective Date, Company may terminate Executive's employment hereunder as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>For Cause</u>. Company may terminate Executive's employment for Cause (as defined below) by written notice by Company to Executive that Executive's employment is being terminated for Cause, which termination shall be effective on the date of such notice or such later date as specified in writing by Company, <u>provided</u> that if Executive has cured the circumstances giving rise to Cause under subsection (D) below (as such cure right may be specifically applicable pursuant to the terms and conditions set forth below) then such termination shall not be effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Without Cause</u>. Company may terminate Executive's employment without Cause, by written notice by Company to Executive that Executive's employment is being terminated without Cause, which termination shall be effective on the date of such notice or such later date as specified in writing by Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Cause Definition</u>. For the purposes of this Agreement, "Cause" shall mean: (A) fraud, embezzlement, or illegal misconduct in connection with Executive's duties under this Agreement; (B) conviction of a felony involving fraud, dishonesty or breach of trust; (C) willful misconduct or gross negligence in the performance of the duties delegated to Executive; (D) breach of this Agreement; or (E) material breach of any non-competition, non-solicitation, non-disclosure, and intellectual property assignment agreement between Executive and Company, including without limitation the Non-Competition and Non-Solicitation Agreement and the Invention and Non-Disclosure Agreement; <u>provided</u> that "Cause" shall not be deemed to have occurred pursuant to subsection (D) hereof unless Executive has first received written notice specifying in reasonable detail the particulars of such ground and that Company intends to terminate Executive's employment hereunder for such ground, and if such ground is curable, Executive has failed to cure such ground within a period of thirty (30) days from the date of his or her receipt of such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Termination by Executive</u>. Notwithstanding anything else contained in this Agreement, from and after the Effective Date, Executive may terminate Executive's employment hereunder as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>For Good Reason</u>. Executive may terminate Executive's employment for Good Reason (as defined below) by written notice by Executive to Company that Executive is terminating Executive's employment for Good Reason, which termination shall be effective thirty (30) days after the date of such notice; <u>provided</u> that if Company has cured the circumstances giving rise to Good Reason then such termination shall not be effective; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Without Good Reason</u>. Executive may terminate Executive's employment without Good Reason by written notice by Executive to Company that Executive is terminating Executive's employment, which termination shall be effective ninety (90) days after the date of such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Good Reason Definition</u>. For the purposes of this Agreement, "Good Reason" shall mean: (A) a material reduction in Executive's then-current Base Salary; (B) a material diminution in Executive's authority, duties, or responsibilities; (C) a material change in the geographic location at which Executive provides services to Company outside of a fifty (50) mile radius from the then-current location without Executive's consent; or (D) any action or inaction by Company that constitutes a material breach of this Agreement; <u>provided</u> that "Good Reason" shall not be deemed to have occurred unless: (1) Executive provides Company with written notice that Executive intends to terminate Executive's employment hereunder for one of the grounds set forth above within thirty (30) days of such ground first occurring, (2) if such ground is capable of being cured, Company has failed to cure such ground within a period of thirty (30) days from the date of such written notice, and (3) Executive terminates Executive's employment within sixty five (65) days from the date that Good Reason first occurs. For purposes of clarification, the above-listed conditions shall apply separately to each occurrence of Good Reason and failure to adhere to such conditions in the event of Good Reason shall not disqualify Executive from asserting Good Reason for any subsequent occurrence of Good Reason.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Termination Due to Disability</u>. Notwithstanding anything else contained in this Agreement, Company may terminate Executive's employment due to Executive's Disability (as defined below) by written notice to Executive that Executive's employment is being terminated as a result of Executive's Disability, which termination shall be effective on the date of such notice or such later date as specified in writing by Company. For the purposes of this Agreement, "Disability" shall mean Executive's incapacity or inability to perform Executive's duties and responsibilities as contemplated herein for one hundred twenty (120) days or more within any one (1) year period (cumulative or consecutive), because Executive's physical or mental health has become so impaired as to make it impossible or impractical for Executive to perform the duties and responsibilities contemplated hereunder. Determination of Executive's physical or mental health shall be determined by the Board (or its designee) after consultation with a medical expert appointed by mutual agreement between Company and Executive who has examined Executive. Executive hereby consents to such examination and consultation regarding Executive's health and ability to perform as aforesaid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Compensation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Base Salary</u>. While Executive is employed hereunder, Executive shall earn a base salary at a bi-weekly rate of Nineteen Thousand Two Hundred Thirty Dollars and Seventy-Six Cents ($19,230.76) (an annualized rate of $500,000) (the "Base Salary"). The Base Salary shall be payable in substantially equal periodic installments, on a bi-weekly basis, in accordance with Company's payroll practices as in effect from time to time. Company shall deduct from each such installment all amounts required to be deducted or withheld under applicable law or under any employee benefit plan in which Executive participates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Annual Bonus</u>. Executive shall be eligible to receive an annual performance bonus (the "Annual Bonus") for all years in which Executive is employed by Company hereunder. The Annual Bonus target shall be fifty percent (50%) of Executive's Base Salary earned during the applicable calendar year. The amount of the Annual Bonus shall be based on factors such as Executive's work performance, Company's financial performance, Company's business forecasts, Company's determination of Executive's achievement of milestones for the applicable year, and economic conditions generally. The actual amount of the Annual Bonus shall be determined by the Board in its sole and absolute discretion. <u>In order to be eligible to receive an Annual Bonus for a given year, Executive must be an active employee of Company on, and not have provided notice of Executive's intent to resign from Company as of, the date that such Annual Bonus is paid, and no Annual Bonus shall be considered earned before that date</u>. Any Annual Bonus for 2025 will be prorated based on the Effective Date of this Agreement. Company shall deduct from the Annual Bonus all amounts required to be deducted or withheld under applicable law or under any employee benefit plan in which Executive participates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Equity</u>. Subject to the approval of the Compensation Committee of the Board of Directors (the "Committee"), Company may grant you a non-qualified stock option intended to qualify as an "inducement" grant under Rule 303A.08 of the NYSE Listed Company Manual (the "Option") outside of but subject to the terms of the Company's 2021 Equity Incentive Plan (the "Plan") for the purchase of an aggregate of 297,600 shares of common stock of Company (the "Shares"). The exercise price per share shall be equal to the closing price of Company's stock on the date of grant by the Committee. The Option shall be subject to all terms, vesting schedules and other provisions set forth in the Plan and in a separate option agreement. Executive specifically acknowledges and agrees that the equity opportunities provided for in this Section, in addition to the other consideration and mutual obligations provided for in the Non-Competition and Non-Solicitation Agreement, constitutes fair and reasonable consideration and mutually-agreed-upon consideration for the Non-Competition restrictions set forth in Section 1 of the Non-Competition and Non-Solicitation Agreement for which Executive is not otherwise entitled to.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Fringe Benefits</u>. Executive shall be entitled to participate in all benefit/welfare plans and fringe benefits provided to employees at the same level as Executive. Executive understands that, except when prohibited by applicable law, Company's benefit plans and fringe benefits may be amended by Company from time to time in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Vacation</u>. Executive's eligibility for vacation time shall be governed by Company's Paid Time Office Policy as in effect from time to time. Executive understands that, except when prohibited by applicable law, Company's Paid Time Office Policy may be amended by Company from time to time in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Reimbursement of Expenses</u>. Company shall reimburse Executive for all ordinary and reasonable out-of-pocket business expenses incurred by Executive in furtherance of Company's business in accordance with Company's policies with respect thereto as in effect from time to time. Executive must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A ("Section 409A") of the Code and the rules and regulations thereunder, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive's employment (or during a shorter period of time specified in this Agreement); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Indemnification</u>. Executive shall be eligible for coverage under Company Directors' and Officers' ("D&O") insurance policies to the same extent and in the same manner to which Company's similarly situated executives are entitled to coverage under Company D&O insurance policies, subject to the terms and conditions of any such Company D&O insurance policies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Forfeiture/Clawback</u>. All compensation described herein shall be subject to any forfeiture or clawback policy established by Company generally for executives from time to time and any other such policy required by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Termination Payments; Severance Benefit</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Payment of Accrued Obligations</u>. Regardless of the reason for any employment termination hereunder, Company shall pay to Executive: (i) the portion of Executive's Base Salary that has accrued prior to any termination of Executive's employment and has not yet been paid; (ii) the portion of Executive's vacation days that have accrued prior to any termination of Executive's employment and has not yet been used; and (iii) the amount of any expenses properly incurred by Executive on behalf of Company prior to any such termination and has not yet been reimbursed (together, the "Accrued Obligations") promptly following the effective date of termination, and otherwise within any timeframe required by law. Executive's entitlement to other compensation or benefits under any Company plan or policy shall be governed by and determined in accordance with the terms of such plan or policy, except as otherwise specified in this Agreement. In the event of Company's termination of Executive's employment for Cause or Executive's termination of Executive's employment without Good Reason, Executive shall be eligible for the Accrued Obligations and shall not be eligible for any severance or severance-type payments, other than as expressly set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Severance in the Event of Termination Without Cause or Resignation for Good Reason</u>. Subject to the terms and conditions of Section 4(c), in the event that Executive's employment hereunder is terminated by Company without Cause or terminated by Executive for Good Reason, then, in addition to the Accrued Obligations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Company shall pay Executive an amount equal to continuation of Executive's monthly Base Salary for a twelve (12) month period, with such payments to be made in accordance with Company's normal payroll practices and schedules, less all customary and required taxes and employment-related deductions.

Subsections (i) is referred to as the "Standard Severance." The Standard Severance is expressly subject to the conditions described in Section 4(c) below, and any payment or benefit made as part of such Standard Severance shall be paid less all customary and required taxes and employment-related deductions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Conditions</u>. Company shall not be obligated to provide Executive any payment and/or benefit described in Section 4(b), other than the Accrued Obligations, unless and until Executive has executed without revocation a separation agreement in a form acceptable to Company, which must be signed by Executive, returned to Company and be enforceable and irrevocable no later than sixty (60) days following Executive's separation from service (the "Review Period"), and which shall include, at a minimum, the provision of separation pay and benefits due from Company to Executive as applicable, a complete general release of claims against Company and its affiliated entities and each of their officers, directors and employees, and terms relating to non-disparagement, non-competition, non-solicitation, confidentiality, cooperation and the like similar in scope, duration and substance to those terms set forth in the Non-Competition and Non-Solicitation Agreement and the Invention and Non-Disclosure Agreement described in Section 5 below. If Executive executes and does not revoke such agreement within the Review Period, then provision of payments and/or benefits shall commence on the first (1st) day following the Review Period, <u>provided</u> that if the last day of the Review Period occurs in the calendar year following the year of termination, then the payment shall not commence until January 2 of such subsequent calendar year, and further <u>provided</u> that, as applied to subsection (i) of Section 4(b) as applicable, the first payments/benefits shall include in a lump sum all amounts that were otherwise payable to Executive from the date of Executive's separation from service occurred through such first payment. As stated in the Non-Competition and Non-Solicitation Agreement, in the event Executive is eligible for garden leave or analogous payments in support of non-competition obligations, then Company reserves the right to offset the Standard Severance with such garden leave or analogous payments to the extent permitted by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>No Other Payments or Benefits Owing; No Duplication of Severance</u>. The payments and benefits set forth in this Section 4 shall be the sole amounts owing to Executive upon termination of Executive's employment for the reasons set forth above and Executive shall not be eligible for any other payments or other forms of compensation or benefits. The payments and benefits set forth in this Section shall be the sole remedy, if any, available to Executive in the event that Executive brings any claim against Company relating to the termination of Executive's employment under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Non-Competition and Non-Solicitation Agreement and the Invention and Non-Disclosure Agreement</u>. In light of the competitive and proprietary aspects of the business of Company, and as a condition of Executive's employment hereunder, Executive agrees to sign and abide by the Non-Competition and Non-Solicitation Agreement and the Invention and Non-Disclosure Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Code Sections 409A and 280G</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that the payments or benefits set forth in Section 4 constitute "non-qualified deferred compensation" subject to Section 409A, then the following conditions apply to such payments or benefits:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any termination of Executive's employment triggering payment of benefits under Section 4 must constitute a "separation from service" under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits can commence. To the extent that the termination of Executive's employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to be provided by Executive to Company at the time Executive's employment terminates), any such payments under Section 4 that constitute deferred compensation under Section 409A shall be delayed until after the date of a subsequent event constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes of clarification, this Section 6(a) shall not cause any forfeiture of benefits on Executive's part, but shall only act as a delay until such time as a "separation from service" occurs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Notwithstanding any other provision with respect to the timing of payments under Section 4 if, at the time of Executive's termination, Executive is deemed to be a "specified employee" of Company (within the meaning of Section 409A(a)(2)(B)(i) of the Code), then limited only to the extent necessary to comply with the requirements of Section 409A, any payments to which Executive may become entitled under Section 4 which are subject to Section 409A (and not otherwise exempt from its application) shall be withheld until the first (1st) business day of the seventh (7th) month following the termination of Executive's employment, at which time Executive shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to Executive under the terms of Section 4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) It is intended that each installment of the payments and benefits provided under Section 4 shall be treated as a separate "payment" for purposes of Section 409A. Neither Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding any other provision of this Agreement to the contrary, this Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section 409A, or the payment of increased taxes, excise taxes or other penalties under Section 409A. The parties intend this Agreement to be in compliance with Section 409A. Executive acknowledges and agrees that Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If any payment or benefit Executive would receive under this Agreement, when combined with any other payment or benefit Executive receives pursuant to a Change of Control (for purposes of this section, a "Payment") would: (i) constitute a "parachute payment" within the meaning of Section 280G the Code; and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then such Payment shall be either: (A) the full amount of such Payment; or (B) such lesser amount (with cash payments being reduced before equity compensation) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes, and the Excise Tax, results in Executive's receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>General</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Notices</u>. Except as otherwise specifically provided herein, any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt.

 

*Notices to Executive shall be sent to the last known address in Company's records or such other address as Executive may specify in writing.* 

 

*Notices to Company shall be sent to:*

Vicarious Surgical Inc.

78 4th Avenue

Waltham, MA 02451

Attention: Chair, Board of Directors

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Modifications and Amendments</u>. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Waivers and Consents</u>. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Assignment</u>. Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of Company's business or that aspect of Company's business in which Executive is principally involved. Executive may not assign Executive's rights and obligations under this Agreement without the prior written consent of Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Governing Law; Jury Waiver</u>. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the law of Massachusetts without giving effect to the conflict of law principles thereof. Any legal action or proceeding with respect to this Agreement shall be brought in the courts of the Commonwealth of Massachusetts or the United States of America for the District of Massachusetts. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT SHALL BE RESOLVED BY A JUDGE ALONE AND EACH OF COMPANY AND EXECUTIVE WAIVES ANY RIGHT TO A JURY TRIAL THEREOF.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Headings and Captions</u>. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Entire Agreement</u>. This Agreement, together with the other agreements specifically referenced herein, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Counterparts</u>. This Agreement may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A scanned or electronic signature (including without limitation, via DocuSign) shall be considered an original for all purposes.

[Signature Page to Follow]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

---

| | | |
|:---|:---|:---|
|  | VICARIOUS SURGICAL INC. | VICARIOUS SURGICAL INC. |
| /s/ Stephen From | By: | /s/ Adam Sachs |
| Stephen From | Name: | Adam Sachs |
|  | Title: | CEO |
| Address: |  |  |

---

## Exhibit 99.1

**Exhibit 99.1**

**Vicarious Surgical Announces Leadership Transition:**

**Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer**

*Adam Sachs, Co-Founder, to Remain on as President*

WALTHAM, Mass. -- (BUSINESS WIRE) – July 31, 2025 -- Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Stephen From as Chief Executive Officer and a member of the Company's Board of Directors (the "Board"), effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company's leadership team.

Mr. From brings over 20 years of leadership in the healthcare and financial industry. He most recently served as CEO of Aruna Bio, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and CEO, and from February 2021 through January 2022 served as Executive Chairman of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space.

Before EyeGate, Mr. From was CFO of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University

"I am honored to join the Vicarious Surgical team at this pivotal time in its evolution. The Company's technology offers a significant advancement from today's surgical approaches with the potential to transform modern surgery and improve outcomes for patients worldwide," said Mr. From. "I look forward to working alongside this talented team and Board to advance our strategic priorities and deliver on the promise of this innovative platform."

"It has been an incredible journey to lead Vicarious Surgical from its inception through pre-clinical testing, and I'm proud of all we've accomplished to date. As I transition into the role of President, I'm excited to welcome Stephen as our new CEO," said Adam Sachs, current Chief Executive Officer, Co-Founder, and Board member. "I believe his leadership and experience are exactly what we need at this pivotal stage, and I look forward to working closely with him to advance our mission of transforming surgical care through innovative robotics."

In connection with the appointment of Mr. From, the Company is also announcing, as required by New York Stock Exchange Listed Company Manual Rule 303A.08 (the "Inducement Rule"), a stock option award to be made to Mr. From as a material inducement to his entering into employment with the Company. The stock option award was approved by the Company's Board and by its Compensation Committee with a grant date of August 7, 2025.

The stock option to be granted to Mr. From will be exercisable for up to 297,600 shares of the Company's Class A common stock, will have an exercise price equal to the closing price of the Class A common stock on the date of grant, and will expire on the ten-year anniversary of the grant date. One-quarter of the stock options will vest and become exercisable on the one-year anniversary of the grant date, and the remainder of the stock options will vest in thirty-six equal consecutive, equal monthly installments thereafter, subject to Mr. From's continued service to the Company through each vesting date and subject to accelerated vesting in certain circumstances. The stock option award will be made outside of the Company's existing 2021 Equity Incentive Plan, as amended (the "Plan"), but will be subject to terms and conditions generally consistent with those in the Plan, other than with respect to such terms and conditions intended to comply with the Inducement Rule.

**About Vicarious Surgical**

Founded in 2014, Vicarious Surgical is a next generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

**Forward-Looking Statements**

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the potential for the Company's technology to improve patient outcomes, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product and service development activities; the potential attributes and benefits of the Company's product candidates and services; the Company's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing license, manufacture, supply and distribution agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company's business, financial condition and results of operations; the Company's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company's filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

**Investor Contact**

Marissa Bych<br> Gilmartin Group<br> marissa@gilmartinir.com

ir@vicarioussurgical.com

**Media Inquiries**

media@vicarioussurgical.com

Source: Vicarious Surgical Inc.